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Newly synthesized membrane proteins are queried
by ubiquitin ligase complexes and triaged between
degradative and nondegradative fates. The mecha-
nisms that convert modest differences in substrate-
ligase interactions into decisive outcomes of
ubiquitination are not well understood. Here, we
reconstitute membrane protein recognition and
ubiquitination in liposomes using purified compo-
nents from a viral-mediated degradation pathway.
We find that substrate-ligase interactions in the
membrane directly influence processivity of ubiquitin
attachment to modulate polyubiquitination. Unex-
pectedly, differential processivity alone could not
explain the differential fates in cultured cells of
degraded and nondegraded clients. Both computa-
tional and experimental analyses identified contin-
uous deubiquitination as a prerequisite for maximal
substrate discrimination. Deubiquitinases reduce
polyubiquitin dwell times preferentially on clients
that dissociate more rapidly from the ligase. This
explains how small differences in substrate-ligase
interaction can be amplified into larger differences
in net degradation. These results provide a concep-
tual framework for substrate discrimination during
membrane protein quality control.INTRODUCTION
Eukaryotic integral membrane proteins insert, assemble, and
mature at the endoplasmic reticulum (ER) (Skach, 2009). Mem-
brane proteins that fail tomature are ubiquitinated by ER resident
ubiquitin ligases and degraded by the proteasome in a pro-
cess termed ER-associated degradation (ERAD) (Vembar and
Brodsky, 2008). ERAD pathways are also utilized for regulatory
control of membrane proteins on the basis of cellular demand(Hampton, 2002; DeBose-Boyd, 2008). Thus, all newly synthe-
sized membrane proteins are triaged between degradative and
nondegradative fates at the ER.
Proper triage is critical to cellular homeostasis and physiology.
Failure to efficiently target misfolded proteins for degradation
can lead to proteotoxicity, cell death, and disease (Chiti and
Dobson, 2006). Conversely, overaggressive surveillance would
result in degradation of functional products and loss-of-function
consequences (Grove et al., 2011). Inappropriate triage of
regulated factors can also lead to imbalanced expression levels
with pathologic effects (DeBose-Boyd, 2008). Thus, achieving
the correct balance in membrane protein triage is vital, but the
mechanisms that regulate client discrimination are not well
understood.
A key step in triage between degradative and nondegradative
fates is client ubiquitination by an ER-resident ubiquitin ligase
(Hirsch et al., 2009). A polyubiquitin tag serves as a signal for
downstream factors to extract themembrane protein and deliver
it to the proteasome for degradation (Vembar and Brodsky,
2008). The acquisition or not of polyubiquitin is therefore a
deciding factor for client triage. The simplest model is one where
clients destined for degradation are recruited to the ligase,
whereas other proteins are not. This paradigm of discrimination,
based solely on ligase access, is common in regulated degrada-
tion. For example, Sic1 is targeted for degradation only after
phosphorylation generates a mark for ubiquitin ligase recruit-
ment (Feldman et al., 1997). Although attractively simple, there
are several reasons to suspect that ligase access alone cannot
provide sufficient discriminatory power in quality control.
First, quality control is usually thought to involve broad ‘‘sur-
veillance’’ of many potential clients, with commitment for degra-
dation of only a minor subset. Second, most quality-control
ligases must recognize a highly diverse range of clients; not
only are there numerous individual proteins, but each one can
be misfolded in myriad ways. This means that a single ‘‘recogni-
tion motif’’ or degron is unlikely, placing constraints on the level
of selectivity that can be achieved by simple interaction. And
third, essentially all newly synthesized proteins are potential
clients early in their biosynthesis before they have folded,
assembled, and matured. Thus, the issue may be less aboutCell 154, 609–622, August 1, 2013 ª2013 The Authors 609
whether a client interacts with a ligase, but rather more subtle
aspects of the nature of the interaction.
Indeed, coimmunoprecipitation (co-IP) and crosslinking
studies showqualitatively similar ligase interactions for degraded
and nondegraded versions of potential clients. For example, the
client Hmg2p interacts with the ligase Hrd1p regardless of
whether Hmg2p is subsequently degraded or not (Gardner
et al., 2001; Sato et al., 2009). Similarly, the ligase-client interac-
tions for degraded and nondegraded forms of TCRa are also
remarkably similar (Ishikura et al., 2010). Thus, ligase access
per se does not obligate client degradation; rather, a more
nuanced model is needed to explain how modest differences in
ligase interaction are converted to large differences in client fate.
Efforts to study this process in mechanistic depth have been
hampered by various challenges. In vitro systems to date are typi-
cally composedofmicrosomes (or semipermeabilizedcells) com-
bined with cytosol (Shamu et al., 1999; Nakatsukasa et al., 2008;
Garza et al., 2009). Although the cytosol is experimentally acces-
sible, themembrane components remain a challenge. Full control
of reactions in the membrane requires the capacity to indepen-
dently reconstitute purified client and ligase complexes. Unfortu-
nately, amisfolded protein client poses considerable obstacles to
expression,purification, and reconstitution. Furthermore, themul-
tiple components and complex topology of ER-resident ligases
(Hirsch et al., 2009) has thus far precluded their functional mem-
brane reconstitution. Thus, it has not been possible to rigorously
examine how the nature of client-ligase interactions in the mem-
brane influences ubiquitination and commitment for degradation.
To circumvent these issues, we turned to virus-mediated
degradation of host membrane protein from the ER. Several
viruses encode membrane proteins that exploit host ubiquitin
ligases for regulateddegradationof keycellularproteins (Isaacson
and Ploegh, 2009). Such systems have yielded key insights into
ERADpreviouslyandprovideseveral attractive features for recon-
stitution studies. First, the client is not recognized on the basis of
misfolding, meaning that a native protein amenable to recombi-
nant production can be used. Second, the system is typically
orthogonal to endogenous pathways and utilizes a single defined
ligase. Third, viral systems are usually rapid, efficient, and robust.
Thus, viral systems of regulated degradation often encapsulate
the salient features of a physiologic process in a simplified format.
In this study, we exploit these advantages to reconstitute with
purified components the ubiquitination of CD4 by the HIV-
encoded protein Vpu. The reconstituted system permitted quan-
titative mechanistic analysis to reveal key aspects of substrate
discrimination and commitment for degradation. We discovered
that modest differences in client-ligase interaction are converted
into clear differences in polyubiquitination by a combination of
processivity differences and deubiquitinases (DUBs) that impact
the dwell time of a degradation mark on potential clients. These
findings have implications for the mechanism underlying mem-
brane protein triage and quality control at the ER.
RESULTS AND DISCUSSION
Experimental System
The HIV-encoded membrane protein Vpu interacts with CD4 at
the ER and routes it for proteasomal degradation (reviewed by610 Cell 154, 609–622, August 1, 2013 ª2013 The AuthorsNomaguchi et al., 2008; Figure S1A available online). Although
Vpu is not a ubiquitin ligase, its phosphorylation at two sites
by casein kinase 2 (CK2) permits a high-affinity interaction
with the SCFbTrCP ubiquitin ligase complex via its F-box protein
bTrCP (Margottin et al., 1998). Ligase recruitment to the ER
leads to ubiquitination of the unstructured cytosolic tail of
CD4. Phospho-Vpu therefore converts the nucleocytoplasmic
SCFbTrCP complex into anERubiquitin ligase thatmediatesselec-
tive degradation of its CD4 client. Importantly, the basic features
of this systemwork in various heterologous systems (Chen et al.,
1993;Schubert et al., 1998;MeusserandSommer, 2004), arguing
against cell-type-specific features in CD4 degradation. The Vpu-
mediated CD4 degradation pathway therefore affords a simpli-
fiedmodel of membrane protein degradationwhosemechanistic
details may be amenable to dissection by in vitro reconstitution.
Our strategywas to first define versionsofCD4andVpu that differ
in their membrane interactions and degradation and then use
these model clients and nonclients to investigate the basis of
substrate discrimination during membrane protein triage.
Transmembrane-Domain-Dependent Interactions
Modulate CD4 Degradation by Vpu
CD4 expression in cultured cells was downregulated in a dose-
dependent manner by coexpression of Vpu (Figure 1A). A phos-
phorylation site Vpu mutant (Vpu-SN; see Table S1 for construct
details) was completely inactive (Figure S1B), as characterized in
earlier work (Schubert and Strebel, 1994; Magada´n et al., 2010).
Changing three residues in the transmembrane domain (TMD) of
Vpu (I17F/V21F/V25L, termed Vpu-M1) largely abolished its
ability to downregulate CD4 (Figure 1A). Similar results were
seen when the Vpu TMD was replaced with heterologous
TMDs (Vpu-M2, and Vpu-M3; Figure S1C). Replacing the TMD
of CD4 with heterologous TMDs (CD4-M1 and CD4-M2) also
rendered it refractory to Vpu downregulation (Figure 1B) unless
the heterologous TMD (CD4-M3) could interact with Vpu (Fig-
ure S1D). Importantly, the various CD4 and Vpu TMDmutant pro-
teins were verified by fractionation experiments to be membrane
inserted (data not shown). Results from the steady-state exper-
iments with the M1 mutants were confirmed by pulse-chase
analysis (Figure S1E). Thus, Phospho-Vpu-mediated CD4 degra-
dation from the ER depends on features of the TMDs of both
proteins (Magada´n and Bonifacino, 2012).
To examine the contribution of TMDs to the CD4-Vpu interac-
tion,weperformedco-IP experiments. TheVpu-SNphosphoryla-
tionmutant permitted interactions to be assessed in the absence
of downstream degradation. As expected (Bour et al., 1995;
Magada´n et al., 2010), Vpu-SN coimmunoprecipitated CD4 (Fig-
ure 1C) and vice versa (Figure S1F). However, a qualitatively
similar interaction by co-IP was also observedwith TMDmutants
of either Vpu or CD4 (Figures 1C, S1F, and S1G). Deleting the
cytosolic domain of CD4 showed amarked (>80%), but not com-
plete, loss in co-IP with Vpu (Figure 1C), consistent with an inter-
action between their cytosolic tails (Bour et al., 1995). Combining
the CD4 cytosolic deletion with a Vpu TMDmutant abolished the
interaction entirely (data not shown). Thus, the CD4-Vpu interac-
tion is bipartite via both the cytosolic and TMD regions.
The contribution of the TMD was judged to be relatively minor
based on the modest 30% reduction in co-IP with the CD4 or
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Figure 1. TMD-Dependent CD4 Degrada-
tion by Vpu
(A) Increasing amounts of Vpu (top) or Vpu-M1
(panel) plasmids were cotransfected with a fixed
amount (100 ng) of CD4 and analyzed 24 hr later by
immunoblotting. The two Vpu bands correspond
to phosphorylated and unphosphorylated forms.
Actin is a loading control. Quantification of CD4 is
shown below the blots.
(B) Wild-type (WT) Vpu or the Vpu-SN phosphor-
ylation mutant (SN) was coexpressed with the
indicated CD4 constructs and analyzed by immu-
noblotting.
(C) HA-tagged Vpu-SN constructs containing the
wild-type or M1 mutant transmembrane domain
were coexpressed with the indicated CD4 con-
structs and analyzed by immunoblotting directly
(5% lysate; top) or after IP with anti-HA antibodies
(bottom).
(D) Quantification of CD4 degradation and inter-
action (by co-IP) for the indicated Vpu-CD4 pairs.
Degradation was analyzed as in (B), and interac-
tion was analyzed as in (C). Mean ± SD from at
least three experiments.
(E) Disrupting TMD-TMD interactions between Vpu
and CD4 markedly reduces CD4 degradation
despite minimal effects on their overall interaction.
See also Figure S1 and Tables S1 and S2.Vpu M1 mutants (Figure 1D). This indicates that the TMDmutant
proteins are engaged in CD4-Vpu complexes to at least 70% the
level as the wild-type pair. Yet, phospho-Vpu-dependent CD4
degradation is almost completely lost (quantified in Figure 1D),
suggesting that even small decreases in interaction are sufficient
to effect a large change in degradation. This mirrors earlier ob-
servations with ER ubiquitin ligases, where degraded versus
nondegraded versions of clients displayed surprisingly minor dif-
ferences in ligase interaction (Gardner et al., 2001; Meacham
et al., 2001; Sato et al., 2009; Ishikura et al., 2010). Thus, the
Vpu-CD4 system and their TMDmutants provide a simple model
system to dissect the mechanistic basis of selective degradation
for subtly different client-ligase interactions in the membrane
(Figure 1E).
In Vitro Reconstitution of CD4 Ubiquitination by a
Vpu-Bound Ubiquitin Ligase
To facilitate in vitro reconstitution of Vpu-mediated CD4 ubiqui-
tination, we isolated ER microsomes from cells expressing HA-Cell 154, 609–62tagged Vpu or phosphorylation-deficient
Vpu-SN. Coimmunoprecipitation experi-
ments showed that Vpu, but not Vpu-
SN, was associated with the SCFbTrCP
complex (Figure 2A). The Vpu-SCFbTrCP
complex was completely stable to 0.8 M
salt wash (Figure S2A), illustrating that
this complex essentially behaves as an in-
tegral membrane ubiquitin ligase. Impor-
tantly, the microsomes were functional
for protein translocation (Figure 2B),allowing 35S-labeled proteins to be introduced into them by
in vitro translation.
Given that Vpu has at most one or two residues in the ER
lumen, we reasoned that the only relevant portion of CD4 for
its selective ubiquitination was the TMD and cytosolic tail. A
‘‘mini-CD4’’ (mCD4) containing only these domains was con-
structed (Table S2) and verified to insert efficiently and correctly
into ER microsomes by in vitro translation (Figure 2C). Although
this construct does not contain a signal peptide, the TMD, now
being positioned near the N terminus, acts as a type I signal
anchor to mediate targeting and insertion (Higy et al., 2004).
Protease protection assays combined with IPs verified that
mCD4 acquires the correct type I topology (Figure 2C). Append-
ing an N-terminal glycosylation site to mCD4 resulted in mCD4
glycosylation (Figure 2C), corroborating its insertion by an inde-
pendent means.
Following mCD4 in vitro translation and insertion, microsomes
were isolated and washed with 0.8 M salt to remove the cytosol
and any noninserted mCD4. Next, ubiquitination reactions were2, August 1, 2013 ª2013 The Authors 611
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Figure 2. Reconstitution of Vpu-Mediated CD4 Ubiquitination on
Microsomes
(A) HEK293-derived rough microsomes (RM) from cells expressing nothing
(control), Vpu-HA, or Vpu-SN-HA were analyzed directly or after anti-HA IPs.
The positions of phosphorylated and unphosphorylated Vpu are indicated.
CRT is the ER resident chaperone calreticulin.
(B) CD4 in vitro translated in the presence of HEK293 RMs is translocated as
evidenced by its glycosylation.
(C) 3F4-mCD4 was in vitro translated with 35S-methionine in the absence or
presence of RMs and subjected to digestion with proteinase K (PK) in the
absence or presence of detergent (Det). A matched construct containing a
consensus glycosylation site (Glyc-mCD4) was also analyzed. The products
were immunoprecipitated using antibodies against the N-terminal 3F4 tag and
analyzed by SDS-PAGE and autoradiography. The bands are as follows: FL,
full-length mCD4; glyc, glycosylated mCD4; PF, protease-protected fragment.
(D) 3F4-mCD4 or Glyc-mCD4 was in vitro translated and translocated into the
indicated RMs from HEK293 cells, and the isolated, high-salt washed RMs
were subjected to a ubiquitination reaction by adding E1 and E2 enzymes, His-
tagged ubiquitin, and ATP. Ubiquitinated products were pulled down via the
His tag and the mCD4 (or Glyc-mCD4) visualized by autoradiography.
See also Figure S2 and Tables S1 and S2.initiated by adding purified E1 and E2 enzymes, together with
tagged-ubiquitin and ATP. Ubiquitin pull-downs followed by
visualization of the radiolabeled mCD4 revealed a ladder of
ubiquitinated mCD4 (Figure 2D). Glycosylated mCD4 was also
ubiquitinated (Figure 2D), verifying that membrane-inserted
mCD4 was being modified. Ubiquitination was dependent on
SCFbTrCP because a parallel reaction with phosphorylation-defi-
cient Vpu-SN failed to be ubiquitinated (Figure 2D), consistent
with its inability to coimmunoprecipitate SCFbTrCP (Figures 2A
and S2A). Furthermore, the absolute dependence on phospho-
Vpu illustrates that endogenous ligases in this system do not
perceivemCD4 as amisfolded protein for ubiquitination. Optimal
polyubiquitination was achieved using a mixture of UbcH3 and612 Cell 154, 609–622, August 1, 2013 ª2013 The AuthorsUbcH5 (Figure S2B), consistent with different E2 enzymes
being optimal for initial ubiquitination versus chain elongation
(Rodrigo-Brenni and Morgan, 2007; Wu et al., 2010). Use of a
K48R mutant ubiquitin showed deficient chain elongation (Fig-
ure S2C). Ubiquitination was not observed when the four lysines
in the tail of CD4 were mutated to arginines (data not shown).
Thus, the Vpu-SCFbTrCP ligase complex ubiquitinates mCD4 on
isolated membranes in vitro, setting the stage for reconstitution
with purified factors.
Reconstitution ofMembrane Protein Ubiquitination with
Recombinant Components
The modularity of the Vpu-CD4 system afforded the opportunity
to assemble it from individual recombinant factors in liposomes
(Figure 3A). We expressed and purified mCD4 and Vpu from
E. coli (Figure 3B), confirmed that purified Vpu can be phosphor-
ylated efficiently by purified Casein Kinase 2 (CK2; data not
shown), and that the cytosolic domain interacted efficiently
with bTrCP in a phosphorylation-dependent manner (Fig-
ure S3A). We then optimized conditions for reconstitution of
mCD4 and Vpu into synthetic liposomes such that most of it
was incorporated in the correct orientation as determined by
protease protection assays (Figure S3B). Co-IP experiments
showed that when mCD4 and Vpu were coincorporated into
the same liposomes, they interacted with each other (Figure 3C).
By contrast, mixing separate liposomes each containing mCD4
or Vpu, followed by solubilization and IP, showed minimal inter-
action (Figure 3C).
Incubation of liposomes containing mCD4 and Vpu with
purified recombinant SCFbTrCP complex (Figure 3B), E1 and E2
enzymes, ubiquitin, and ATP resulted in polyubiquitination of
mCD4 (Figure 3D). Ubiquitination was strictly dependent on
Vpu phosphorylation because neither unphosphorylated wild-
type Vpu nor CK2-treated Vpu-SN supported mCD4 ubiquitina-
tion (Figure 3D). As expected from earlier work (Duda et al., 2008;
Saha and Deshaies, 2008), the speed and efficiency of ubiquiti-
nation was improved by Nedd8 modification of the SCFbTrCP
complex (Figures S3C and S3D).
The cytosolic domains of CD4 and phospho-Vpu, despite the
capability to interact weakly (Singh et al., 2012), failed to produce
substantial CD4 ubiquitination (Figures 3E and 3F). By contrast,
tethering these His-tagged cytosolic domains to the surface of
membranes via Ni2+-NTA lipid permitted ubiquitination (Figures
3E and 3F). However, the ubiquitination was substantially less
processive than membrane-inserted mCD4 and Vpu as evi-
denced by fewer ubiquitins on the substrate (around three to
seven, compared to over ten). This effect was not due to mem-
brane insertion per se because replacing the TMDs of Vpu and
mCD4 with oppositely charged interacting coiled coils permitted
highly processive ubiquitination in the absence of anymembrane
(Figures 3E and 3F).
These results rigorously illustrate that Vpu-mediated CD4
ubiquitination requires no additional factors beyond the SCFbTrCP
complex, its associated E2 enzymes, E1, and ubiquitin. More-
over, the data suggest that the cytosolic domains of CD4 and
Vpu interact too weakly to mediate efficient ubiquitination in
solution. However, constraining them to a membrane surface
allows some ubiquitination, presumably by limiting their diffusion
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Figure 3. TMD-Dependent mCD4 Ubiquiti-
nation with Purified Factors
(A) Diagram depicting the purified system.
(B) Coomassie-stained gels of recombinant puri-
fied proteins.
(C) Co-IP analysis of recombinant Vpu and mCD4
in reconstituted proteoliposomes. Radiolabeled
mCD4 and recombinant Vpu were incorporated
either separately or together into liposomes, and
the indicated samples were mixed, solubilized,
and subjected to IP with anti-Vpu or control IgG.
The samples before and after IP were analyzed by
immunoblotting for Vpu and autoradiography for
mCD4, respectively.
(D) Liposomes reconstituted with mCD4 alone,
with Vpu (WT), or with Vpu-SNwere incubatedwith
CK2 (as indicated) and ubiquitination factors (E1,
UbcH3, UbcH5c, Myc-ubiquitin, ATP). mCD4 was
immunoprecipitated and the samples blotted for
ubiquitin or mCD4.
(E and F) Vpu and mCD4 combinations as de-
picted in (E) were subjected to ubiquitination and
analyzed as in (D).
See also Figure S3 and Tables S1 and S2.and degrees of freedom to enhance their interaction. The
TMDs add to this interaction, presumably by orienting the
cytosolic domains and by interacting within the membrane to
further stabilize the Vpu-CD4 complex. Prolonged interactionCell 154, 609–62permits the ligase time to sequentially
build long ubiquitin chains. This estab-
lishes a membrane protein ubiquitination
reaction that relies on TMD-dependent
substrate-ligase interaction to maximize
processivity.
Substrate-Ligase Interactions
Modulate Ubiquitination
Processivity
We next asked whether the discrimina-
tion of correct from incorrect substrates
observed in cultured cells could be
recapitulated in vitro. To facilitate quanti-
tative analysis, we modified the recombi-
nant system to contain radiolabeled
substrate generated by in vitro transla-
tion (Figure S4A). The translated and
microsome-inserted substrate was sepa-
rated from the translation extract and
bulk microsomal proteins and mixed
with purified lipids and recombinant Vpu
prior to reconstitution into proteolipo-
somes. The final proteoliposomes in this
radiolabeled recombinant system con-
tained Vpu and radiolabeled mCD4, but
undetectable levels of proteins from the
original in vitro translation reaction and
more than 95% removal of microsomal
proteins (data not shown). The remainderof the components (for ubiquitination) was from recombinant
sources. As expected, mCD4 ubiquitination in the radiolabeled
recombinant system displayed a strict dependence on phos-
pho-Vpu, showed high processivity and was easily quantifiable2, August 1, 2013 ª2013 The Authors 613
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Figure 4. Substrate Discrimination in Cells, In Vitro, and in Purified Systems
(A) Analysis of discrimination in a radiolabeled recombinant ubiquitination system. Radiolabeled mCD4 (or mCD4-M1) isolated from in vitro translation reactions
(see Figure S4A) was coreconstituted with recombinant Vpu into liposomes. The purified proteoliposomes were subjected to ubiquitination with recombinant
SCFbTrCP, purified E1 and E2 enzymes, His6-tagged ubiquitin, and ATP. The reaction at different time points was stopped and analyzed for ubiquitinated mCD4
via pull-downs of the tagged ubiquitin (Ub PDs). Total mCD4 in the reaction is shown in the bottom panel. The graph below the autoradiograph depicts the
densitometry profiles of the 5 min samples, with the individual ubiquitinated species indicated.
(B) Ubiquitination reactions as in (A) were either analyzed directly (top) or after solubilization and native IP using anti-HA or control antibodies (bottom). The HA-
tagged Vpu recovered in the IP was analyzed by blotting, and the mCD4 was analyzed by autoradiography.
(legend continued on next page)
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given that only the substrate was radiolabeled (Figures S4B
and S4C).
Unexpectedly, the Vpu-mediated ubiquitination of mCD4 and
mCD4-M1 was nearly identical (Figure 4A). Co-IP experiments
showed that the Vpu-mCD4-M1 interaction in vitro was reduced
modestly relative to the Vpu-mCD4 interaction (Figure 4B), very
similar to co-IP experiments in cells (Figure 1D). Furthermore,
crosslinking analysis in proteoliposomes showed that bTrCP
crosslinks almost equally well to mCD4 versus mCD4-M1 (Fig-
ure S4D). Importantly, ubiquitination was strictly dependent on
the Vpu-SCF complex (Figures S4B and S4E), arguing against
any other contaminating activities in the system that could
explain the lack of difference. Thus, discrimination of correct
from incorrect clients in the minimal in vitro system was incon-
gruent with degradation efficiencies observed in cultured cells.
Similar results were observed when Vpu-M1 was used for
mCD4 ubiquitination (Figures S4C and S4F). The lack of discrim-
ination was observed over a wide range of concentrations (Fig-
ure S5A) and could not be easily explained by excessively high
(or low) substrate or ligase levels. However, careful quantification
of the ubiquitination profiles from the in vitro reactions revealed a
subtle but highly reproducible difference in the high molecular
weight species (see densitometry profiles, Figures 4A, S4F,
and S5B). This reduction reflects a slight deficiency in building
particularly long chains for the mutant mCD4-Vpu pairs relative
to the wild-type pair, suggesting reduced processivity of ubiqui-
tin addition.
Indeed, analysis of ubiquitination profiles with finer temporal
resolution showed that at very short time points (30 s), mCD4-
M1 was indistinguishable from mCD4 (Figure 4C). Only at later
times is a difference seen preferentially for longer ubiquitin chain
lengths. Thus, ubiquitins are initially added identically to mCD4
and mCD4-M1, consistent with the crosslinking results showing
that Vpu-bound bTrCP ‘‘sees’’ these two proteins almost equally
well (Figure S4D). However, mCD4-M1 presumably dissociates
slightly faster from the Vpu-ligase complex than mCD4. This
would give mCD4-M1 slightly less time than mCD4 to acquire
ubiquitins. Although this may not be significant for a single
encounter, the additive effect of multiple encounters would ex-
plain the difference preferentially seen for long ubiquitin chains.
We therefore conclude that modest differences in interaction
translate to differences in processivity of ubiquitin addition that
translate to differences in long-chain modified substrates.
Discrepant Substrate Discrimination in Reconstituted
versus Native Systems
Although the processivity differences in ubiquitination in vitro are
consistent with similarly subtle differences in interaction by co-(C) Analysis of ubiquitination reactions as in (A) at short time points.
(D) CD4 ubiquitination in cells. The indicated combinations of Vpu and CD4 were
MG132) for 5 hr, subjected to IP with anti-CD4, and analyzed by immunoblotting f
shows quantification (mean ± SD; n = 3) of relative CD4 ubiquitination normalize
(E) Ubiquitination reactions of in vitro translated mCD4 or mCD4-M1 in Vpu-con
below the autoradiograph.
(F) Summary of the results of interaction and ubiquitination analysis from cell cultu
wild-type (wt) to M1 mutant recovered by co-IP (interaction) and observed to be
discrimination.
See also Figures S4 and S5 and Tables S1 and S2.IP, neither result matches the substantially greater difference in
degradation for wild-type versus mutant TMDs. Indeed, Vpu-
mediated CD4 ubiquitination in cultured cells under conditions
of proteasome inhibition showed a clear 5- to 10-fold differ-
ence between CD4 and CD4-M1 (Figure 4D). This corresponded
not only to decreased degradation (e.g., Figure 1), but also to
decreased dislocation as judged by the absence of a deglycosy-
lated product upon proteasome inhibition (Figure S5C). The
cultured cell system therefore converts modest differences in
CD4-Vpu interaction into substantial differences in CD4 poly-
ubiquitination, dislocation, and degradation. This feature of
discrimination is only partially recapitulated in the radiolabeled
recombinant system as a slight difference in processivity (Fig-
ure 4A). By contrast, use of ER microsomes instead of reconsti-
tuted proteoliposomes displayed clear discrimination between
wild-type and mutant mCD4-Vpu pairs (Figures 4E and S5D).
Thus, the radiolabeled recombinant in vitro system seems to
lack some feature(s) that imparts substrate discrimination to
the crude in vitro and cellular systems (summarized in Figure 4F).
KineticModeling Suggests aRole forDeubiquitination in
Substrate Discrimination
A clue to the missing feature came from the observation that
enhanced discrimination in the crude in vitro systemwas accom-
panied by shorter ubiquitin chains (Figure 5A). This suggested
that the crude system contained deubiquitination activity, which
has been speculated to influence the timing of degradation from
the ER (Blount et al., 2012; Lederkremer and Glickman, 2005;
Feldman and van der Goot, 2009). Indeed, ubiquitinated mCD4
produced in the radiolabeled recombinant systemwas deubiqui-
tinated when incubated in a crude cell lysate (Figure S6A). Ubiq-
uitin removal occurred progressively from the distal end of the
chain (Figure S6B), illustrating that mCD4 is subject to
exodeubiquitination.
To understand how deubiquitination can influence substrate
discrimination, we turned to kinetic modeling. Pioneering studies
by Pierce et al. (2009) established a kinetic description of
SCFbTrCP-mediated ubiquitination of b-catenin peptide. We
expanded and revised the kineticmodel in a fewminor ways (Fig-
ures 5B and S6C) and verified that it produced a ubiquitination
profile roughly comparable to that observed experimentally (Fig-
ure 5C, green bars, compare to Figure 5A).
We then incorporated DUBs into the model such that they can
remove the terminal ubiquitin from the chain. Using a DUB con-
centration of 0.4 mM, and a Kcat of 0.5 s
1 (Hassiepen et al.,
2007), the model produces a ubiquitination profile similar to
that observed experimentally in the crude in vitro Vpu-mCD4
system (Figure 5C, orange bars, compare to Figure 5A). Usingcotransfected with FLAG-ubiquitin, treated with proteasome inhibitor (40 mM
or FLAG-ubiquitin and CD4. Vpu levels in the lysate are also shown. The graph
d to total CD4.
taining HEK293 microsomes. Quantification of the 30 min time point is shown
re, crude in vitro, and recombinant in vitro systems. The approximate ratios of
polyubiquitinated are indicated. The recombinant in vitro system shows poor
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Figure 5. Kinetic Modeling of Ubiquitination
without DUBs versus with DUBs
(A) Normalized ubiquitination profiles of reactions
performed in liposomes (green) versus micro-
somes (orange).
(B) Kinetic model of substrate ubiquitination,
substrate dissociation, and deubiquitination. See
Figure S6C for additional details.
(C) Output of the kinetic model at 20 s using the
indicated parameters without (green) or with
(orange) DUBs. The relative amounts of the indi-
vidual ubiquitinated species are plotted.
(D) Relationship between polyubiquitination
(defined as four or more ubiquitins), koff, and DUB
activity predicted by the model analyzed at 20 s.
See also Figure S6.this as a starting point, we used the model to examine the role of
DUB activity in the relationship between client-ligase interaction
and polyubiquitination. In the absence of DUB activity, we
observed that substrate polyubiquitination (defined here as
four or more ubiquitins) in a single encounter decreased pro-
gressively with increasing Koff values for the substrate-ligase
interaction (Figure 5D). This is easily rationalized because
rapid substrate dissociation from the ligase provides less time
to build ubiquitin chains. In the presence of DUB activity, a qual-
itatively similar relationship between Koff and polyubiquitination
was observed (Figure 5D). However, overall polyubiquitination
was less than without DUBs (particularly at higher Koff values),
and the curve was progressively steeper with increasing DUB
concentration.
The net effect of this is to increase discrimination (as defined
by fold differences in polyubiquitination) between two sub-
strate-ligase pairs of differing rates of dissociation (Koff). For
example, in the absence of DUBs (Figure 5D, green curve), a
2-fold increase in Koff (from 0.4 to 0.8) results in an 2.2-fold
decrease in polyubiquitination (from 9.4% to 4.3%). In the
presence of high DUB activity (Figure 5D, red curve), that same
2-fold increase in Koff results in an 8.3-fold decrease in poly-
ubiquitination (from 1.66% to 0.2%). Thus, DUB activity can
noticeably improve substrate discrimination in this model, albeit
at the expense of overall ubiquitination efficiency. This point is
also revealed by inspecting the kinetic model output at different
time points (Figures S6D and S6E).
DUB Activity Enhances Substrate Discrimination by Vpu
Adding cytosol to the radiolabeled recombinant system during
the ubiquitination reaction decreased overall polyubiquitination
and ubiquitin chain length and increased discrimination between
mCD4 and mCD4-M1 (Figure 6A). Pretreatment of the cytosol
with Ubiquitin-aldehyde partially reversed each of these effects,
illustrating that their origin was likely to involve DUBs (Figures 6A
and 6B). The same results, albeit somewhat muted, were ob-616 Cell 154, 609–622, August 1, 2013 ª2013 The Authorsserved when the mCD4-Vpu-M1 pair
was analyzed (Figure S7A). The incom-
plete reversal with ubiquitin-aldehyde
can be explained by incomplete inhibition
of DUB activity (Figure S7B), whereas theslightly reduced discrimination over time seems to be due to
DUBs losing activity sooner than the SCF (Figure S7C). These
technical quirks notwithstanding, at least one contributing factor
to discrimination imparted by cytosol can be attributed to DUB
activity.
Use of a purified DUB (the catalytic domain of USP2) in lieu of
cytosol also imparted discrimination to the radiolabeled recom-
binant mCD4-Vpu system in a concentration-dependent manner
(Figures 6C–6E). Consistent with predictions from the kinetic
modeling, discrimination came at the expense of ubiquitination
efficiency (Figure 6F). Other purified DUBs (USP7, Ataxin3) could
also impart discrimination in this assay, albeit to different extents
that correlated with their relative catalytic activities (data not
shown). It therefore appears that DUB activity, rather than a spe-
cific DUB, is the crucial determinant in imparting discrimination
in this system.
Evidence for a Role of DUBs in Substrate Discrimination
in Cultured Cells
An important insight from our in vitro andmodeling studies is that
a nondegraded client (i.e., CD4-M1) is nevertheless ubiquiti-
nated, but that the ubiquitin chains are rapidly counteracted
and rarely long enough to trigger degradation. Thus, lack of
degradation is not due to a lack of ligase interaction or ubiquiti-
nation, but to rapid deubiquitination. This conclusion makes two
testable predictions. First, nondegraded clients should be tran-
siently modified with ubiquitin chains that do not usually reach
a sufficient length to trigger degradation. Second, reducing
cellular DUB activity should mute substrate discrimination by
preferentially reducing the levels of normally nondegraded sub-
strates. Each of these predictions was examined to evaluate
the role of DUBs in cultured cells.
We analyzed ubiquitination of clients without proteasome
inhibitor pretreatment and attempted to detect individual
ubiquitinated species rather than the smear typically seen with
prolonged inhibitor-treated samples. Strikingly, ubiquitinated
products were observed at similar levels for CD4 in the presence
of Vpu, CD4-M1 in the presence of Vpu, andCD4 in the presence
of Vpu-M1 (Figure 7A). However, the ubiquitin chains were
clearly different: whereas CD4 intended for degradation con-
tained a substantial amount of polyubiquitin, CD4-M1 contained
primarily one to three ubiquitins. This difference is readily
apparent when the ubiquitination profiles are plotted and
normalized to the amount of substrate (Figure 7A, graph). The
same was observed for CD4 coexpressed with Vpu-M1.
With proteasome inhibitor pretreatment for 3 hr, poly-
ubiquitination of CD4 was increased, consistent with its eventual
destiny of degradation (Figure 7B). By contrast, the oligoubiqui-
tination of CD4-M1 decreased modestly (Figure 7B). With even
longer proteasome inhibition, the oligoubiquitin species become
undetectable relative to the polyubiquitin smear, which preferen-
tially accumulates on CD4 and not CD4-M1 (e.g., see Figure 4D).
This can be explained by the observation that proteasome
inhibition prevents ubiquitin recycling, leading to depletion of
free ubiquitin within 30 min to 3 hr (Melikova et al., 2006). Under
these conditions, substrates that are transiently ubiquitinated
and deubiquitinated will diminish in their ubiquitination in
the face of limiting ubiquitin, whereas polyubiquitinated sub-
strates that would have been degraded by the proteasome will
accumulate.
These observations suggest that in cultured cells, CD4 and
CD4-M1, which interact similarly with the Vpu-ligase complex,
are both ubiquitinated. However, the slightly weaker-interacting
CD4-M1 contains fewer ubiquitins and is not degraded. This is
presumably due to constant DUB activity that limits chain
growth. Inhibiting DUB activity should therefore preferentially
reduce the levels of CD4-M1, thereby reducing its discrimination
fromCD4. Indeed, treatment of cells with the broadly acting DUB
inhibitor PR-619 (Tian et al., 2011) reduced Vpu-mediated
discrimination of CD4 from CD4-M1 by selectively reducing the
levels of the latter (Figure 7C). Similar effects were seen with
the CD4-Vpu-M1 pair. Prolonged treatment, although toxic to
cells, led to nearly complete elimination of discrimination in the
CD4-Vpu system (data not shown). Thus, as seen in vitro,
optimal discrimination in cultured cells relies on DUB activity.
Conclusions and Perspective
Our in vitro, cellular, and in silico analysis of Vpu-mediated CD4
degradation shed light on general mechanisms underlying client
discrimination, an event of critical importance in membrane pro-
tein quality and quantity control. We propose that discrimination
with respect to eventual degradation is imparted by a combina-
tion of four parameters. First is the encounter of a potential client
with the ligase complex, a prerequisite for ubiquitination. Second
is the length of time this interaction is maintained, which would
directly influence the number of ubiquitins that are added in
each encounter (i.e., processivity). Third is the accessibility and
activity of counteracting DUBs, which influences the length
and dwell time of a ubiquitin chain. And fourth is downstream
commitment events that determine client fate such as polyubi-
quitin-dependent engagement of the p97 complex for extraction
(Wolf and Stolz, 2012), incorporation into COPII vesicles for
ER export (Gillon et al., 2012), or achievement a configuration
that markedly reduces ligase interaction. Uncommitted clientswould re-enter the above cycle, with any delay in re-engaging
the ligase resulting in rapid, unopposed deubiquitination to the
ground state.
In the absence of DUB activity, our modeling and reconstitu-
tion studies suggest that discrimination would rely completely
on large differences in client-ligase interaction. This is likely to
be the case for degradation of soluble proteins from the lumen
of ER, where access to the cytosolically disposed ligase activity
is controlled by various upstream factors such as chaperones,
adaptors, and glycosylation enzymes (Vembar and Brodsky,
2008). Discrimination for lumenal clients is therefore enforced
by a chaperone network to triage clients between repeated
folding attempts and delivery to a ligase, similar to reactions
occurring during quality control in the cytosol (Buchberger
et al., 2010).
By contrast, ligase access in the plane of the membrane is
qualitatively different because the client and ligase are con-
strained to only two dimensions within a continuous compart-
ment, and the catalytic activity of the ligase is accessible to the
client without any topological rearrangement. Ligase-client inter-
actions for membrane proteins may therefore be rather promis-
cuous and frequent, albeit relatively brief in most instances. It is
in this regimen that discrimination relies on DUB activity to
convert modest differences in interaction into larger differences
in polyubiquitin acquisition and degradation. Our modeling and
purified DUB experiments suggest that DUB activity, rather
than a particular DUB, is sufficient for effecting discrimination.
Nevertheless, it is plausible that individual quality-control path-
ways utilize different DUBs that are recruited to the site of ubiq-
uitination (Blount et al., 2012). Indeed, many DUBs have been
observed to interact with ligases for reasons that are unclear
(Sowa et al., 2009).
The role for DUBs proposed here in controlling the generation
of a degradation signal is worth distinguishing from downstream
roles for DUBs. Once a degradation signal is generated and re-
cruits ubiquitin binding proteins (such as the p97 complex;
Wolf and Stolz, 2012), the substrate is committed for degrada-
tion. From this point, DUBs are thought to be involved in
removing ubiquitins for threading through p97 (Ernst et al.,
2009) and the proteasome (Ventii and Wilkinson, 2008). Given
these multiple sites of action, it is not surprising that modulating
deubiquitination in slightly different ways can have different out-
comes for substrate degradation. For example, expression of a
heterologous DUB free in the cytosol versus tethered to p97
affects different types of clients at different stages of the degra-
dation process (Ernst et al., 2011). Similarly, a single client can be
both stimulated and inhibited in its degradation depending on
which DUB is knocked down (Sowa et al., 2009). These observa-
tions underscore the advantage of biochemically resolving a
complex multistep process into individual reactions that can
be mechanistically analyzed.
The appreciation of a role for DUBs in discrimination helps
to explain otherwise puzzling aspects of quality control. For
example, Vpu interacts sufficiently well with CD4 and bTrCP to
not only coimmunoprecipitate with them, but also to retain
them in the ER (Magada´n et al., 2010; Magada´n and Bonifacino,
2012). Despite these robust interactions and the fact that ubiqui-
tination in the CD4-Vpu-SCFbTrCP complex occurs in mereCell 154, 609–622, August 1, 2013 ª2013 The Authors 617
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Figure 6. DUB Activity Contributes to Substrate Discrimination In Vitro
(A) The radiolabeled recombinant system was used to analyze mCD4 versus mCD4-M1 ubiquitination in the presence of BSA, HEK293 cell cytosol, or cytosol
pretreated with ubiquitin-aldehyde. Note that ubiquitin-aldehyde only partially inhibits DUB activity (Figure S7B). The graph below the autoradiograph depicts the
densitometry profiles of the 5 min samples.
(B) The ratio of polyubiquitination acquired on mCD4 divided by that acquired on mCD4-M1 in a parallel reaction is defined as discrimination. This value was
determined for three experiments performed as in (A), quantified, and shown in the graph (mean ± SD).
(legend continued on next page)
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Figure 7. Evidence of a Role for DUBs in
Substrate Discrimination in Cultured Cells
(A) Analysis of CD4 ubiquitination as in Figure 4D,
but without proteasome inhibitor pretreatment.
The positions of CD4 containing one and three
ubiquitins are indicated. Below the blot is shown
the ubiquitination profiles, normalized for the
relative amount of total CD4, for the reactions
containing CD4 versus CD4-M1.
(B) Analysis similar to (A) on cells pretreated
without or with proteasome inhibitor (40 mM
MG132 for 3 hr). The bottom panel shows immu-
noblots of total lysates, confirming that unconju-
gated ubiquitin levels are depleted several-fold
after proteasome inhibition.
(C) Vpu-mediated degradation of CD4 in the
absence and presence of the deubiquitinase in-
hibitor PR-619. Seven hours following transfection
of the indicated plasmids, the cells were incubated
for 13 hr without or with 25 mM PR-619 before
harvesting and analysis by immunoblotting. Two
exposures of the CD4 blot are shown. The results
are quantified in the graph.
See also Tables S1 and S2.seconds, CD4 degradation is remarkably slow (t1/2 of 30 min
or more). This can now be rationalized by the observation
that very high DUB activity markedly reduces the proportion of
substrates that acquire a polyubiquitin degradation signal with
each ligase encounter, and the length of time that signal persists.
This means that a large number of encounters are needed to get
substantial degradation, explaining the relatively slow degrada-
tion of CD4 in cultured cells relative to its rapid polyubiquitination
in vitro.(C) Ubiquitination reactions of mCD4 versus mCD4-M1 in the radiolabeled recombinant system suppleme
combinant USP2-CD deubiquitinase. Reaction time was 30 s, although similar results were seen at later tim
(D) Densitometry analysis of the reactions from (C) without or with 8 mM USP2-CD.
(E) Discrimination plotted as a function of USP2-CD concentration derived from (C).
(F) Relative polyubiquitination efficiency of mCD4 and mCD4-M1 as a function of USP2-CD concentration.
mCD4 in the absence of USP2-CD.
See also Figure S7 and Tables S1 and S2.
Cell 154, 609–62For substrates whose ligase interaction
is marginally less stable, ubiquitins would
be initially added at the same rate. How-
ever, the ligase would dissociate slightly
earlier, allowing unopposed DUBs to
rapidly deubiquitinate the substrate. The
combination of less polyubiquitin produc-
tion and shorter dwell time necessarily re-
duces opportunities for downstream
steps in degradation, resulting instead in
regeneration of the nonubiquitinated sub-
strate. This provides a mechanism for
achieving markedly different substrate
half-lives for two clients with very similar
ligase interactions. Although seemingly
wasteful, the energy utilized for repeated
de- and reubiquitination is employed toachieve substantial discrimination by essentially summing the
outputs of numerous encounters.
This concept, a variation on kinetic proofreading, has been
proposed to explain the order of degradation of key cell-cycle
regulators (Rape et al., 2006). In that system, the APC ligase
was shown to display differential processivity toward its clients
due to differences in their interactions. The processivity differ-
ences were inversely related to their rate of degradation,
providing an explanation for howproteins withmodestly differentnted with the indicated concentrations of the re-
e points as well.
Values were normalized to the value observed for
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APC interaction are nevertheless discriminated effectively.
Similar principles are used in signaling to convert modest differ-
ences in an input stimulus into large differences in output by
exploiting multisite phosphorylation with competing dephos-
phorylation (Malleshaiah et al., 2010; Trunnell et al., 2011). By
linking the output to a maximally phosphorylated state,
competing dephosphorylation can effectively dampen output
until a certain threshold input is reached.
Analogous principles utilizing multistep ubiquitination and
competing deubiquitination may explain how two membrane
proteins of very similar structure, such as Hmg2 in the presence
of low versus high sterol, are decisively discriminated despite
similar interactions with quality-control ligases. Reconstitution
of such quality-control events in a tractable biochemical system
represents an important future goal. We anticipate that many
ligase interactions with membrane proteins will display modest
differences between folded and misfolded versions. This is
because ligases need to recognize a wide range of unrelated
clients that are unlikely to share any uniform ‘‘degron,’’ necessi-
tating a rather broad sampling of potential clients using rela-
tively weak interactions. Our findings suggest that achieving a
wide dynamic range of degradation within a relatively narrow
range of interactions involves exploiting the dynamic interplay
between ubiquitination and deubiquitination, adding a previ-
ously unappreciated dimension to the mechanism of protein
quality control.
EXPERIMENTAL PROCEDURES
Plasmids and Antibodies
Vpu- and CD4-derived constructs were modifications of published plasmids
(Magada´n et al., 2010) and described in Tables S1 and S2. The interacting
coiled-coil segments used in Figure 3F have been described (Wang et al.,
2011). Expression plasmids for SCFbTrCP and UbcH3 were from R. Deshaies
and B. Schulman (Duda et al., 2008; Saha and Deshaies, 2008). Antibodies
were from the following sources: anti-CD4 (Leica Microsystems), anti-Vpu
(Magada´n et al., 2010), anti-FLAG (Sigma-Aldrich), anti-Myc (Cell Signaling),
anti-HA (Roche), anti-Actin (Abcam), anti-Cul1 (Invitrogen), anti-bTrCP
(Invitrogen), anti-3F4 (Signet), anti-His6 (QIAGEN), anti-GAPDH (Sigma), and
anti-CRT (Abcam).
Recombinant Proteins
Vpu and mCD4 were expressed in BL21 (DE3) pLysS cells and purified from
inclusion bodies under denaturing conditions (with 6 M Urea) and the His tag
removed by TEV protease. TheCul1/Rbx1 and bTrCP138/Skp1 subcomplexes
were expressed, purified, and assembled as before (Li et al., 2005; Saha and
Deshaies, 2008). Unmodified SCFbTrCP complex was used in Figures 3D, 3F,
4B, S4B, S4C, and S4E, whereas Nedd8-modified complex was used in all
other experiments. UbcH3 was expressed and purified as before (Saha and
Deshaies, 2008). Other proteins (Ube1, UbcH5c, various tagged ubiquitins,
APPBP1/Uba3, UbcH12, Nedd8, and USP2 catalytic domain) were purchased
from Boston Biochem.
Cell Culture Studies
HeLa, HEK293, and Flp-In 293 T-Rex cells (Invitrogen) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) medium with 10% fetal bovine
serum, 2 mM glutamine, and antibiotics. Transfections utilized Lipofectamine
2000 (Invitrogen). Pulse-chase analysis, ubiquitination analysis, IPs, SDS-
PAGE, immunoblotting, and microsome isolation were as before (Furman
et al., 2002; Magada´n et al., 2010). Native IPs were performed on samples
solubilized in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1% digitonin plus protease inhibitor cocktail (Roche).620 Cell 154, 609–622, August 1, 2013 ª2013 The AuthorsIn Vitro Translation and Reconstitution
Translation in rabbit reticulocyte lysate and protease protection assays has
been described (Sharma et al., 2010; Fons et al., 2003). Reconstitutions
were as before (Mariappan et al., 2011) and typically contained 5–1,000 ng
recombinant Vpu, mCD4, 1% (w/v) DeoxyBigCHAP, and 200 mg unilamellar
liposomes in a total volume of 100 ml. Detergent was removed with 40 mg
Bio-beads and the proteoliposomes collected by centrifugation for use in ubiq-
uitination assays. Lipid composition was typically 16:3.8:0.2 ratio of phospha-
tidyl-choline, phosphatidyl-ethanolamine, and rhodamine-PE. Ni-NTA lipid
was included at 0.5 mol percent in Figure 3F.
In Vitro Ubiquitination
Ubiquitination reactions typically contained 2mMATP, 500 nMSCFbTrCP com-
plex, and ubiquitin-charged E2s (5 mM UbcH3 and 0.2 mM UbcH5c) in the
following buffer: 30 mM Tris-HCl (pH 7.5), 120 mM NaCl, 5 mM MgCl2, and
2 mM DTT. The reaction was carried out at 25C for various times. Samples
were denatured in 2% SDS and boiled for 3 min prior to downstream analysis.
His6-ubiquitin conjugates were purified using immobilized Co2+ resin.
Miscellaneous
SDS-PAGE used Tris-Tricine gels. Radioactive signals were detected on
film for figures and phosphor screen for quantitation. Kinetic modeling em-
ployed KinTek explorer as described (Pierce et al., 2009) with details given
in Figure S6C. For further details, please refer to Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
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